Vitality Watch

Dossier pubmed preclinical 25-may-2026
Animal model, organoid, or cell-culture result — not yet human

A sustained NADsupplementation-biosynthesis nanoplatform for metabolic restoration in aged bone regeneration.

Key claim: A sustained NAD supplementation-biosynthesis nanoplatform (N/S@M@P) restored NAD/NADH and ATP in senescent BMSCs, reduced their senescent fraction, and substantially improved bone regeneration in aged bone defects.

Abstract

Increasing NADlevels has demonstrated promising therapeutic potential for treating aging-related skeletal disorders. However, for existing bone defects in aged individuals, it remains a formidable challenge to achieve localized and sustained NADrestoration while overcoming poor NADdelivery efficiency and impaired endogenous biosynthesis in senescent cells. Herein, this study developed a sustained NADsupplementation-biosynthesis nanoplatform, N/S@M@P, to stimulate aged bone regeneration. This platform employs dual-mesoporous silica nanoparticles to highly load NADand controllably load NADbiosynthesis activator, establishing a “supplementation-biosynthesis” strategy for rapid NADreplenishment and sustained NADmetabolic restoration in senescent bone marrow-derived mesenchymal stromal cells (BMSCs). Meanwhile, N/S@M enhanced cellular uptake efficiency by 41.0% through regulating the endocytic pathways of senescent BMSCs. After incorporation into an injectable hydrogel scaffold, N/S@M@P enabled sustained particle release over 14 days, supporting prolonged metabolic restoration. This strategy increased the NAD/NADH ratio by 11.2-fold and increased ATP production by 3.25-fold in senescent BMSCs. In aged bone defects, N/S@M@P reduced the proportion of senescent BMSCs to 21.2% at day 7 and increased the bone volume fraction (BV/TV) by 119% at 4 weeks. These findings demonstrate that this nanoplatform can effectively restore the functions of senescent BMSCs, providing a promising therapeutic strategy for aging-related bone regeneration.

Why this matters

NAD-restoration pitches for aged tissue repair have mostly relied on systemic precursor dosing (NR/NMN) with weak human translation; this preclinical platform instead couples local sustained precursor release with support for endogenous biosynthesis, giving a cleaner mechanistic test of whether coordinated NAD/ATP rescue in a senescent stromal compartment can drive a regenerative endpoint. It sits within an established NAD-restoration axis — the delivery design is the novelty, not the biology — and remains a mouse/BMSC-level result with no human data.

Source

Link

Briefing card

A sustained NADsupplementation-biosynthesis nanoplatform for metabolic restoration in aged bone regeneration.
Stage: preclinical · pubmed · 25-may-2026

If you follow NAD precursor research for bone or stem-cell aging, this is a preclinical delivery-platform result in aged mice — no human bone-healing outcomes yet.

A sustained NAD supplementation-biosynthesis nanoplatform (N/S@M@P) restored NAD/NADH and ATP in senescent BMSCs, reduced their senescent fraction, and substantially improved bone regeneration in aged bone defects.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.bioactmat.2026.05.016

build build 880 · 2bcef25 · 2026-11-18